Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Assets (2021 - 2025)

Lyra Therapeutics has reported Assets over the past 5 years, most recently at $36.1 million for Q4 2025.

  • Quarterly results put Assets at $36.1 million for Q4 2025, down 45.58% from a year ago — trailing twelve months through Dec 2025 was $36.1 million (down 45.58% YoY), and the annual figure for FY2025 was $36.1 million, down 45.58%.
  • Assets for Q4 2025 was $36.1 million at Lyra Therapeutics, down from $43.7 million in the prior quarter.
  • Over the last five years, Assets for LYRA hit a ceiling of $142.6 million in Q4 2023 and a floor of $36.1 million in Q4 2025.
  • Median Assets over the past 5 years was $77.5 million (2021), compared with a mean of $86.6 million.
  • Biggest five-year swings in Assets: skyrocketed 100.43% in 2022 and later plummeted 60.21% in 2025.
  • Lyra Therapeutics' Assets stood at $54.9 million in 2021, then skyrocketed by 100.43% to $110.0 million in 2022, then increased by 29.67% to $142.6 million in 2023, then plummeted by 53.47% to $66.3 million in 2024, then crashed by 45.58% to $36.1 million in 2025.
  • The last three reported values for Assets were $36.1 million (Q4 2025), $43.7 million (Q3 2025), and $52.6 million (Q2 2025) per Business Quant data.